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To date, investigations of Pneumocystis jirovecii circu-
lation in the human reservoir through the dihydropteroate
synthase (DHPS) locus analysis have only been conducted
by examining P. jirovecii isolates from immunosuppressed
patients with Pneumocystis pneumonia (PCP). Our study
identifies P. jirovecii genotypes at this locus in 33 immuno-
competent infants colonized with P. jirovecii contemporane-
ously with a bronchiolitis episode and in 13 adults with
PCP; both groups of patients were monitored in Amiens,
France. The results have pointed out identical features of P.
jirovecii DHPS genotypes in the two groups, suggesting
that in these groups, transmission cycles of P. jirovecii
infections are linked. If these two groups represent sentinel
populations for P. jirovecii infections, our results suggest
that all persons parasitized by P. jirovecii, whatever their
risk factor for infection and the form of parasitism they
have, act as interwoven circulation networks of P. jirovecii. 
D
ihydropteroate synthase (DHPS) is the enzymatic tar-
get of sulfonamides, which are the major drugs for
Pneumocystis pneumonia (PCP) prophylaxis or treatment
(1). Pneumocystis jirovecii (human-specific Pneumocystis)
organisms with nonsynonymous mutations at nucleotide
positions 165 and 171 on the DHPS locus have been
detected in HIV-infected patients with PCPwho had previ-
ously been treated with sulfonamides (2–14). Prior expo-
sure to sulfonamide drugs has been identified as a
predictor of mutant genotypes (2–12). In addition, the city
of patient residence has also been identified as an inde-
pendent risk factor (6,8), a factor that supports the hypoth-
esis that P. jirovecii is transmitted from infected treated
patients to susceptible untreated patients, either directly or
through a common environmental source. The analysis of
P. jirovecii DHPS locus may thus serve as a useful circula-
tion marker of the microorganism in the human reservoir.
To date, investigations of P. jirovecii circulation
through the DHPS locus analysis have only been per-
formed by examining isolates from immunosuppressed
adults with PCP (8,15,16). However, Pneumocystis infec-
tions may cover a wide spectrum of clinical signs and
symptoms; colonization with Pneumocystis in immuno-
competent infants at risk for primary infection may consti-
tute a large part of this spectrum (17,18). Genotyping of P.
jirovecii at the internal transcribed spacer (ITS) locus
showed that these infants were infected with similar geno-
types as those previously reported in compromised hosts
with PCP; this similarity is compatible with the hypothesis
that both groups of patients make up a common human
reservoir for the fungus (19).
The existence of similar genomic characteristics at
another locus, in particular at the DHPS locus, among P.
jirovecii isolates from these two groups would provide
additional arguments in favor of the fungus’ circulating
within a reservoir made up of persons with different clini-
cal forms of P. jirovecii infection. For these reasons, we
retrospectively investigated for DHPS genotyping archival
P. jirovecii isolates from immunocompetent infants colo-
nized with P. jirovecii and from immunocompromised
adults with PCP. Both groups of patients lived in the same
French city. The results of this study were reported in part
in a conference report (20).
Materials and Methods
Atotal of 58 archival P. jirovecii isolates obtained from
58 patients (45 infants and 13 adults) were retrospectively
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Forty-five archival nasopharyngeal aspirates (NPA)
obtained from 45 nonpremature, immunocompetent
infants (median age 4.3 months [range 1.9–11.8]; sex ratio
26 boys and 19 girls) were examined. The 45 infants were
hospitalized in the period from November 1999 to April
2001. The specimens initially tested positive for P.
jirovecii by a polymerase chain reaction (PCR) assay that
amplifies a portion of the gene encoding the mitochondri-
al large sub-unit rRNA(mtLSUrRNA) (17). All infants ini-
tially had an acute respiratory syndrome compatible with a
diagnosis of bronchiolitis and no patent immunodeficien-
cy. The presence of P. jirovecii in these infants was consid-
ered to reflect merely a colonization. Indeed, clinical
improvement was obtained with short-term hospitalization
(1–12 days), despite the absence of specific treatment for
the fungus. Furthermore, P. jirovecii was associated with
the respiratory syncytial virus or with bacteria (Moraxella
catarrhalis, Haemophilus influenzae, Streptococcus pneu-
moniae, Bordetella pertussis) in 35 of 45 infants. None had
a past history of sulfonamide treatment. The infants’ char-
acteristics are summarized in Table 1.
Thirteen archival bronchoalveolar lavage (BAL) speci-
mens obtained from 13 immunosuppressed adults in whom
PCP was diagnosed were also examined. The 13 patients
were hospitalized in the period from June 1996 to
November 2001. The specimens initially tested positive
for  P. jirovecii by microscopy examination that used
methanol-Giemsa stain and an immunofluorescence assay
(MonofluoKit  Pneumocystis; Bio-RAD, Marnes la
Coquette, France), and by the PCR at mtLSUrRNA. The
underlying conditions were HIV infection (nine patients),
renal transplantation (two patients), and long-term corti-
costeroid treatment for systemic lupus erythematosus (one
patient) and for hepatic granulomatosis (one patient). None
of the patients had P. jirovecii prophylaxis with sulfon-
amide drugs in the 3 months preceding the BAL retrieval.
The patients’ characteristics are summarized in Table 1.
DNAs extracted from NPA and BAL were stored at –20°C
until they were typed. 
The  P. jirovecii DHPS locus was analyzed by
PCR–restriction fragment length polymorphism (RFLP).
The DHPS sequence was first amplified by a nested PCR
assay. The two rounds of PCR were performed under the
same conditions. Each reaction mixture contained the fol-
lowing reagents at the indicated final concentrations: 10
mmol/L Tris-HCl (pH 8.8), 0.1% Tween 20 (vol/vol), 2.5
mmol/L MgCl2, 200 µmol each deoxynucleoside triphos-
phate (dNTP set, Eurogentec, Seraing, Belgium), 0.6
µmol/L each oligonucleotide primer, and 0.02 U DNA
polymerase (Red Goldstar DNA polymerase,
Eurogentec)/µL. The first PCR round was conducted with
primer pair AHUM (5′- GCG CCT ACA CAT ATT ATG
GCC ATT TTAAAT C-3′) and BHUM (5′- CAT AAA CAT
CAT GAA CCC G -3′) (14) by using a “touch-down” pro-
gram. In the first cycle, the denaturation step was 92°C for
30 s, the annealing step was 52°C for 1 min, and the exten-
sion step was 72°C for 1 min. This cycle was repeated 10
times but with each annealing step at 1°C lower tempera-
ture than the preceding cycle. Subsequently, the last cycle,
with an annealing at 42°C, was repeated 20 times. The sec-
ond PCR round was performed with primer pair CPRIM (5′-
CCC CCA CTT ATA TCA-3′) and DPRIM (5′- GGG GGT
GTT CATTCA-3′) (21), for 30 cycles consisting of denat-
uration at 94°C for 30 s, annealing at 50°C for 1 min, and
extension at 72°C for 1 min. The PCR products from the
first and the second rounds underwent electrophoresis on a
1.5% agarose gel containing ethidium bromide to visualize
the expected bands of 766 bp and 269 bp, respectively. To
avoid contamination, each step (reagent preparation,
extraction, and amplification) was performed in different
rooms with different sets of micropipettes and using barri-
er tips. PCR mixtures and the extraction step were pre-
pared in a laminar-flow cabinet. Rooms required for
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Table 1. Characteristics of 45 infants and 13 adults from the University Hospital of Amiens, France, for whom Pneumocystis jirovecii 
organisms were examined at the dihydropteroate synthase locus 
Characteristics  Infants  Adults 
Risk factor for Pneumocystis infection  Young age
a  Immunodeficiency
b 
No. of patients  45  13 
Median age (range)  4.3 mo (1.9–11.8)  35 y (29–67) 
Sex ratio, M/F  26/19  10/3 
Period of specimen retrieval  November 1999–April 2001  June 1996–November 2001 
Kind of specimens  Nasopharyngeal aspirate  Bronchoalveolar lavage 
Method of P. jirovecii detection  PCR assay
c  Both microscopy
d and PCR assay 
Form of Pneumocystis infection  Colonization
e  Pneumocystis pneumonia 
aYoung age
 renders it compatible with primary Pneumocystis infection.
 
bHIV infection (n = 9), renal transplant (n = 2), and long-term corticosteroid treatment (n = 2).  
cPCR, polymerase chain reaction assay, at the mitochondrial large sub-unit rRNA gene.  
dMethanol-Giemsa stain and immunofluorescence assay (Bio-Rad, Marnes la Coquette, France).  
eClinical improvement observed despite the absence of treatment for the fungus. amplified DNAmanipulation were continuously submitted
to an airflow with UV decontamination (SPRW 30 GR4;
Paragerm, Inc., Paris, France). 
To monitor for possible contamination, a negative con-
trol (ultrapure distilled water) was included in each PCR
step. The RFLP assay was performed with two restriction
enzymes, according to the manufacturer’s recommenda-
tions (Promega Corporation, Madison, WI). One part of the
nested PCR products was digested with the restriction
enzyme AccI, and another part with HaeIII, which make
possible the detection of mutations at nucleotide positions
165 and 171, respectively (5) The restriction profiles were
visualized by electrophoresis of each digested product on a
1.5% agarose gel with ethidium bromide, as described in
Figure 1. The mutations inhibit the restriction enzyme
activity. Thus, a wild genotype was shown, after digestion
with AccI, by two fragments of 181 bp and 88 bp, and after
digestion with HaeIII, by two other fragments of 173 bp
and 96 bp. A mutant genotype that has a mutation at
nucleotide position 165 (change from Ato G, corresponding
to a change from Thr to Ala at aminoacid position 55) was
shown, after digestion with AccI, by only one uncut frag-
ment of 269 bp, and after digestion with HaeIII, by the two
fragments of 173 bp and 96 bp. Amutant genotype that has
a mutation at nucleotide position 171 (change from C to T,
corresponding to a change from Pro to Ser at aminoacid
position 57) was shown after digestion with AccI, by the
two fragments of 181 bp and 88 bp, and after digestion with
HaeIII, by only one uncut fragment of 269 bp. A double
mutant genotype, which has mutations at nucleotide posi-
tions 165 and 171, was shown, after digestion with either
AccI or HaeIII, by an uncut fragment of 269 bp.
Results
The amplification of P. jirovecii DNA by using the
DHPS-based PCR assay was positive for 33 of 45 NPA
from infants that initially tested positive with the PCR
directed at the mtLSUrRNAgene, whereas it was success-
ful for 13 of 13 BAL specimens from adults. In each pos-
itive specimen with the DHPS-based PCR assay, the
RFLP technique led to identification of a wild P. jirovecii
DHPS genotype. However, mixed infections were diag-
nosed in three infants and one adult. Indeed, in three (9%)
of the 33 NPAfrom infants,the wild genotype was associ-
ated with a mutant genotype. In one infant, the mutant
genotype had a mutation at nucleotide position 165,
whereas in two infants, it had a mutation at nucleotide
position 171. In one (8%) of the 13 BAL from adults, the
wild genotype was also associated with a mutant geno-
type, which had a mutation at nucleotide position 171. No
infants or adults were infected with a mutant genotype
either singly or with a double mutant genotype. The
results are detailed in Table 2.
Discussion
Most studies on P. jirovecii DHPS genotyping have
focused on the relationship between P. jirovecii DHPS
mutants and prior sulfonamide exposure on the one hand,
and PCP outcome on the other hand (2–13,22–24). We
have used the DHPS locus analysis differently, as a mark-
er for studying the potential circulation of the fungus in the
human reservoir, as it was recently used by Beard et al. and
Huang et al. (8,15,16). Although a multilocus genotyping
was recently reported as an efficient system for P. jirovecii
characterization (25), in this study, we only analyzed the
DHPS locus because it still remains the sole marker of cir-
culation. We also obtained the first data on the analysis of
P. jirovecii DHPS locus in immunocompetent infants at
risk for primary Pneumocystis infection. 
The first step of this analysis required a PCR assay. The
amplification failed to give positive results for 12 of the 45
NPA from infants who initially tested positive for P.
jirovecii by using the PCR at mtLSUrRNA. This differ-
ence in sensitivity between the two PCR assays can be
explained by the fact the mtLSUrRNA gene is present in
many copies within each P. jirovecii genome, whereas the
folic acid synthesis gene, encoding the DHPS, is thought to
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Figure 1. Identification of Pneumocystis jirovecii dihydropteroate
synthase (DHPS) genotypes. Electrophoresis on 1.5% agarose
gel of DHPS polymerase chain reaction products after digestion
with AccI (upper line) and HaeIII (lower line). M, molecular weight
marker (123 Gibco BRL; Cergy Pontoise, France). Lane 1: double
mutant genotype; lanes 2 and 5: wild genotype; lane 3: mixed
infection with a wild genotype and a mutant genotype that has the
mutation at nucleotide position 165; lane 4: mixed infection with a
wild genotype and a mutant genotype which has the mutation at
nucleotide position 171.be present in only one copy (26). This difference is partic-
ularly manifest on specimens collected by noninvasive
means, such as NPA, in which the amount of P. jirovecii is
usually low. Indeed, NPAessentially recover cells from the
upper respiratory tract, whereas the fungus primarily
infects the alveolar spaces. Despite these difficulties, the
identification of P. jirovecii DHPS genotypes was success-
ful for three fourths of the samples we examined.
Most investigations of mutations on the P. jirovecii
DHPS locus have used the direct sequencing of PCR prod-
ucts (3,4,6–8,10,11,14–16,22,23). More recently, a single-
strand conformation polymorphism assay has been
described as an alternative method for detecting DHPS
mutations (12,27). We used the RFLP assay in this study
since this method has a lower cost, is less time-consuming
(5,28), and is more efficient for detecting mixed infections
than direct sequencing (L. Diop Santos, pers. comm.). The
use of restriction enzymes AccI and HaeIII for the diges-
tion of the PCR products showed two mutations at
nucleotide positions 165 and 171, as described above. The
RFLP assay of P. jirovecii DHPS gene was assessed by
Helweg-Larsen et al., who have examined 27 BAL speci-
mens containing a mixture of wild and mutant DHPS
genotypes, previously determined by direct sequencing
(28). For detecting mutations at nucleotide positions 165
and 171 on P. jirovecii DHPS sequence, these researchers
found a 100% concordance between DHPS genotypes
determined by AccI and HaeIII restriction enzyme cleav-
age and by sequencing. Thus, the RFLP assay appears to
be a reliable method for discriminating wild and mutant
DHPS genotypes.
Mutations at nucleotide positions 165 and 171 have
been correlated with prior sulfonamide treatment or pro-
phylaxis (2–12). In our study, since none of the infants or
adults had this medical history, the presence of P. jirovecii
DHPS mutants has to be discussed. Because of the young
age and, consequently, the short medical history of the
infants, we could easily ensure that none had had prior
exposure to sulfonamides. Conversely, this exposure
throughout the adults’ lifetimes cannot strictly be ruled
out. These difficulties have previously been raised by
Huang et al., who have pointed out the need for a standard-
ized definition of exposure to sulfonamides (29). In partic-
ular, the period during which sulfonamides have not been
used, preceding patient sampling, to define the absence of
selective pressure, varies according to the experience of
each medical team. At any rate, in our study, no adults
were treated with sulfonamides in the 3 months before
BAL retrieval. In this group of patients, we detected P.
jirovecii DHPS mutants with a frequency of 8%. This find-
ing may reflect a basic level of infections caused by
mutants in the absence of direct selective pressure; their
presence is related to an incidental acquisition of the
microorganism from humans treated with sulfonamides,
either directly or through hypothetical environmental
stages. In the same way, this hypothesis may explain the
presence of DHPS mutants in the infant group.
Airborne transmission of the fungus from host to host
has been demonstrated in rodent models (30), and several
observations suggest that interindividual transmission
occurs in humans (31,32). Moreover, Pneumocystis organ-
isms infecting each mammalian species are host-specific,
and the hypothesis of an animal reservoir for P. jirovecii
can be excluded (33). Although an exosaprophytic form of
the fungus cannot be ruled out, these data point toward the
potential for the specific host to serve as its own reservoir
and for PCP in humans as an anthroponosis with humans
as a reservoir for P. jirovecii. 
The 8% frequency with which we have detected
mutants in PCP patients from Amiens who had no sulfon-
amide exposure is close to the figure reported for a similar
group of patients in Milan, Italy (4% [2]) and in
Copenhagen (10.5% [4]), while it appears lower than the
rate in Rome (17% [11]), Tokyo (25% [23]), and various
U.S. cities (15%–81% [3,6–8,16]). In France, data on
DHPS genotypes concern patients living in Paris or Lyon,
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Table 2. Pneumocystis jirovecii dihydropteroate synthase (DHPS) genotypes in immunocompetent infants with colonization and in 
immunosuppressed adults with Pneumocystis pneumonia, University Hospital of Amiens, France 
Nucleotide at position (amino acid at position) 
DHPS genotype  165 (55)  171 (57)  Infants  Adults 
Wild genotype
a   A (Thr)  C (Pro)  30  12 
Double mutant genotype
a  G (Ala)  T (Ser)  –
b  – 
Wild genotype + mutant genotype
c   A/G (Thr/Ala)  C (Pro)  1  – 
Wild genotype + mutant genotype
d   A (Thr)  C/T (Pro/Ser)  2  1 
Wild genotype + double mutant genotype
e  A/G (Thr/Ala)  C/T (Pro/Ser)  –  – 
Undetermined genotype  –  –  12
f  – 
aInfection with a single genotype. 
b–, absence. 
c, d, e Mixed infections related to the association of a wild genotype with a mutant genotype. 
cMutant genotype with a mutation at nucleotide position 165 (amino acid position 55). 
dMutant genotype with a mutation at nucleotide position 171 (amino acid position 57). 
eDouble mutant with both mutations at nucleotide positions 165 and 171. 
fAbsence of DHPS amplification despite initial detection by polymerase chain reaction at mtLSUrRNA. 
 as recently reported by Latouche et al. and Nahimana et al.,
respectively (12,13). The frequency of mutants in PCP
patients who had no prior sulfonamide treatment or pro-
phylaxis reaches 25% in Paris (13), and 29% in Lyon (12).
The low proportion of mutants in Amiens in comparison to
Paris and Lyon may be related to different features of P.
jirovecii epidemiology in these cities. Amiens (population
150,000) is characterized by a low incidence of AIDS and
PCP (34). Conversely, in Paris and its suburbs, a mega-
lopolis of 10 million people, the incidence of these two
infections is 30 times as high (34). In Lyon, the second
largest city in France, this incidence is 10 times higher than
in Amiens (34). Consequently, use of sulfonamides is
widespread in Paris and Lyon, favoring the emergence of
mutants and provoking a high risk for incidental acquisi-
tion of these mutants, even in patients not directly exposed
to sulfonamides. This hypothesis is strengthened by a
recent report of Miller et al., concerning patients in
London, which showed that the decrease of sulfonamide
prophylaxis use, related to the introduction of high-active
antiretroviral therapy since 1996 conversely generated a
reduction of mutant DHPS genotypes in London (36%
compared to 16%) (35). Available frequencies of mutants
in PCP patients living in Europe who had no prior sulfon-
amide exposure are shown in Figure 2. 
We detected mutants in immunocompetent infants col-
onized with P. jirovecii and in immunossuppressed adults
with PCP with frequencies of 9% and 8%, respectively.
Besides these similar frequencies, the most frequent P.
jirovecii DHPS genotype was the wild genotype. Mutant
genotypes have only been detected within mixed infec-
tions. On the whole, genomic characteristics of P. jirovecii
organisms at the DHPS locus in the two patient popula-
tions living in the same city are similar. In the United
States, Beard et al. observed different genomic features at
this locus among P. jirovecii isolates from adults and
deceased infants (36). For these reasons, those researchers
suggested that transmission cycles for P. jirovecii infec-
tion in infants and adults were independent. However,
whether the two individual groups lived in the same
American city was not specified. Conversely, our results
of genotyping based on DHPS locus analysis suggest that
these transmission cycles are linked, the two patient
groups being part of a common reservoir in which the fun-
gus may circulate.
If one considers that both of these patient groups may
represent sentinel populations for P. jirovecii infections,
other persons infected with P. jirovecii may also be active-
ly involved in the circulation of the fungus. Indeed, new
detection tools such as PCR assays have shown that pul-
monary colonization with P. jirovecii occurs in patients
with diverse levels of immunodeficiency (37) and in
immunocompetent patients with lung diseases (38,39).
Such assays have also shown that P. jirovecii can transient-
ly parasitize immunocompetent healthcare workers after
contacts with PCP patients (40). Our positive results of
DHPS genotyping on specimens collected by noninvasive
means (NPA) ensure further investigations of P. jirovecii
circulation involving such populations, for whom invasive
sampling cannot easily be performed. In fact, all para-
sitized persons, whatever their predisposition to P. jirovecii
acquisition and the clinical form of P. jirovecii infection
they have, may reflect a wide human reservoir of which all
components are not yet characterized. New insights into
the P. jirovecii reservoir could provide better prophylactic
measures against P. jirovecii transmission and, conse-
quently, PCP.
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Figure 2. Frequencies of Pneumocystis jirovecii dihydropteroate
synthase mutants in patients who had Pneumocystis pneumonia
and no prior sulfonamide exposure, from diverse European cities.
Amiens, France (the present study), Paris (13), Lyon (12),
Copenhagen (4), Milan, Italy (2), Rome (11), and London (35). References 
1. U.S. Public Health Service (USPHS) and Infectious Diseases Society
of America (IDSA). USPHS/IDSA guidelines for the prevention of
opportunistic infections in persons infected with human immunodefi-
ciency virus. MMWR Morb Mortal Wkly Rep 1999;48:1–59.
2. Ma L, Kovacs JA, Cargnel A, Valerio A, Fantoni G, Atzori C.
Mutations in the dihydropteroate synthase gene of human-derived
Pneumocystis carinii isolates from Italy are infrequent but correlate
with prior sulfa prophylaxis. J Infect Dis 2002;185:1530–2.
3. Ma L, Borio L, Masur H, Kovacs JA. Pneumocystis carinii dihy-
dropteroate synthase but not dihydrofolate reductase gene mutations
correlate with prior trimethoprim-sulfamethoxazole or dapsone use. J
Infect Dis 1999;180:1969–78.
4.  Helweg-Larsen J, Benfield TL, Eugen-Olsen J, Lundgren JD,
Lundgren B. Effects of mutations in Pneumocystis carinii dihy-
dropteroate synthase gene on outcome of AIDS-associated P. carinii
pneumonia. Lancet 1999;354:1347–51.
5. Diop Santos L, Lacube P, Latouche S, Kac G, Mayaud C, Marteau M,
et al. Contribution of dihydropteroate synthase gene typing for
Pneumocystis carinii f.sp.  hominis epidemiology. J Eukaryot
Microbiol 1999;46 (Suppl):S133–4.
6. Kazanjian P, Armstrong W, Hossler PA, Burman W, Richardson J,
Lee CH, et al. Pneumocystis carinii mutations are associated with
duration of sulfa or sulfone prophylaxis exposure in AIDS patients. J
Infect Dis 2000;182:551–7.
7. Kazanjian P, Locke AB, Hossler PA, Lane BR, Bartlett MS, Smith
JW, et al. Pneumocystis carinii mutations associated with sulfa and
sulfone prophylaxis failures in AIDS patients. AIDS 1998;12:873–8.
8. Huang L, Beard CB, Creasman J, Levy D, Duchin JS, Lee S, et al.
Sulfa or sulfone prophylaxis and geographic region predict mutations
in the Pneumocystis carinii dihydropteroate synthase gene. J Infect
Dis 2000;182:1192–8.
9. Armstrong W, Meshnick S, Kazanjian P. Pneumocystis carinii muta-
tions associated with sulfa and sulfone prophylaxis failures in
immunocompromised patients. Microbes Infect 2000;2:61–7.
10. Mei Q, Gurunathan S, Masur H, Kovacs JA. Failure of co-trimoxa-
zole in Pneumocystis carinii infection and mutations in dihy-
dropteroate synthase gene. Lancet 1998;351:1631–2.
11. Visconti E, Ortona E, Mencarini P, Margutti P, Marinaci S, Zolfo M,
et al. Mutations in dihydropteroate synthase gene of Pneumocystis
carinii in HIV patients with Pneumocystis carinii pneumonia. Int J
Antimicrob Agents 2001;18:547–51.
12. Nahimana A, Rabodonirina M, Zannetti G, Meneau I, Franciolo P,
Bille J, et al. Association between a specific Pneumocystis jiroveci
dihydropteroate synthase mutation and failure of pyrimethamine/sul-
fadoxine prophylaxis in HIV-positive and -negative patients. J Infect
Dis 2003;188:1017–23.
13. Latouche S, Lacube P, Maury E, Bolognini J, Develoux M, Girard
PM, et al. Pneumocystis jiroveci dihydropteroate synthase genotypes
in French patients with pneumocystosis: a 1998–2001 prospective
study. Med Mycol 2003;41:533–7.
14. Lane BR, Ast JC, Hossler PA, Mindell DP, Bartlett MS, Smith JW, et
al. Dihydropteroate synthase polymorphisms in Pneumocystis carinii.
J Infect Dis 1997;175:482–5.
15. Beard CB, Carter JL, Keely SP, Huang L, Pieniazek NJ, Moura IN, et
al. Genetic variation in Pneumocystis carinii isolates from different
geographic regions: implications for transmission. Emerg Infect Dis
2000;6:265–72.
16. Huang L, Friedly J, Morris AM, Carter JL, Turner JR, Merrifield C,
et al. Pneumocystis carinii dihydropteroate synthase genotypes in
HIV-infected persons residing in San Francisco: possible implications
for disease transmission. J Eukaryot Microbiol 2001;48:137–8S.
17. Nevez G, Totet A, Pautard JC, Raccurt C. Pneumocystis carinii detec-
tion using nested-PCR in nasopharyngeal aspirates of immunocom-
petent infants with bronchiolitis. J Eukaryot Microbiol 2001;48
(Suppl):S122–3. 
18. Vargas SL, Hughes WT, Santolaya ME, Ulloa AV, Ponce CA, Cabrera
CE, et al. Search for primary infection by Pneumocystis carinii in a
cohort of normal, healthy infants. Clin Infect Dis 2001;32:855–61.
19. Totet A, Pautard JC, Raccurt C, Roux P, Nevez G. Genotypes at the
internal transcribed spacers of the nuclear rRNA operon of
Pneumocystis jiroveci in nonimmunosuppressed infants without
severe pneumonia. J Clin Microbiol 2003;41:1173–80.
20. Totet A, Latouche S, Lacube P, Pautard JC, Jounieaux V, Roux P, et
al.  Pneumocystis carinii dihydropteroate synthase genotypes in
immunocompetent infants and immunosuppressed adults from the
same French geographic region. Am J Respir Crit Care Med
2002;165 (Suppl). [Abstract 639].
21. Demanche C, Berthelemy M, Petit T, Polack B, Wakefield AE, Dei-
Cas E, et al. Phylogeny of Pneumocystis carinii from 18 primate
species confirms host specificity and suggests coevolution. J Clin
Microbiol 2001;39:2126–33.
22. Navin TR, Beard CB, Huang L, del Rio C, Lee S, Pieniazek NJ, et al.
Effect of mutations in Pneumocystis carinii dihydropteroate synthase
gene on outcome of P. carinii pneumonia in patients with HIV-1: a
prospective study. Lancet 2001;358:545–9.
23. Takahashi T, Hosoya N, Endo T, Nakamura T, Sakashita HK, Imura
K, et al. Relationship between mutations in dihydropteroate synthase
of Pneumocystis carinii f. sp. hominis isolates in Japan and resistance
to sulfonamide therapy. J Clin Microbiol 2000;38:3161–4.
24. Meshnick SR. Drug-resistant Pneumocystis carinii. Lancet
1999;354:1318–9.
25. Wakefield AE, Lindley AR, Ambrose HE, Denis MC, Miller RF.
Limited asymptomatic carriage of Pneumocystis jiroveci in human
immunodeficiency virus–infected patients. J Infect Dis
2003;187:901–8.
26. Volpe F, Dyer M, Scaife JG, Darby G, Stammers DK, Delves CJ. The
multifunctional folic acid synthesis fas gene of Pneumocystis carinii
appears to encode dihydropteroate synthase and hydroxymethyldihy-
dropterin pyrophosphokinase. Gene 1992;112:213–8.
27. Ma L, Kovacs JA. Rapid detection of mutations in the human-derived
Pneumocystis carinii dihydropteroate synthase gene associated with
sulfa resistance. Antimicrob Agents Chemother 2001;45:776–80.
28. Helweg-Larsen J, Eugen-Olsen J, Lundgren B. Rapid detection of
dihydropteroate polymorphism in AIDS-related Pneumocystis carinii
pneumonia by restriction fragment length polymorphism. Scand J
Infect Dis 2000;32:481–3. 
29. Huang  L, Morris AM, Beard CB. Pneumocystis carinii dihy-
dropteroate synthase mutations and treatment with sulfa or sulfone
regimens: a proposal for standardized definitions for clinical evalua-
tion. J Eukaryot Microbiol 2001;48(Suppl):S180–1. 
30.  Dumoulin A, Mazars E, Seguy N, Gargallo-Viola D, Vargas S,
Cailliez JC, et al. Transmission of Pneumocystis carinii disease from
immunocompetent contacts of infected hosts to susceptible hosts. Eur
J Clin Microbiol Infect Dis 2000;19:671–8.
31. Helweg-Larsen J, Tsolaki AG, Miller RF, Lundgren B, Wakefield AE.
Clusters of Pneumocystis carinii pneumonia: analysis of person-to-
person transmission by genotyping. Q J Med 1998;91:813–20.
32. Miller RF, Ambrose HE, Novelli V, Wakefield AE. Probable mother-
to-infant transmission of Pneumocystis carinii f. sp. hominis infec-
tion. J Clin Microbiol 2002;40:1555–7.
33. Durand-Joly I, Aliouat el M, Recourt C, Guyot K, Francois N,
Wauquier M, et al. Pneumocystis carinii f. sp. hominis is not infec-
tious for SCID mice. J Clin Microbiol 2002;40:1862–5.
34. Institut de veille sanitaire. Surveillance du SIDA en France. Bulletin
Epidémiologique Hebdomadaire 2002;27:133–8.
35. Miller RF, Lindley AR, Ambrose HE, Malin AS, Wakefield AE.
Genotypes of Pneumocystis jiroveci isolates obtained in Harare,
Zimbawe, and London, United Kingdom. Antimicrob Agents
Chemother 2003;47:3979–81.
36. Beard CB, Fox MR, Hanzlick RL, Guarner J, Carter JL, Del Rio C, et
672 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 4, April 2004
RESEARCHal. Independent transmission cycles for Pneumocystis carinii pneu-
monia in immunocompetent infants and in adults with AIDS. In:
Abstracts of the VII International Worskhops on Opportunistic
Protists; Cincinnati, Ohio; 2001 June 13–16; Abstract PL94.
37. Nevez G, Raccurt C, Vincent P, Jounieaux V, Dei-Cas E. Pulmonary
colonization with Pneumocystis carinii in human immunodeficiency
virus–negative patients: assessing risk with blood CD4+ T cell
counts. Clin Infect Dis 1999;29:1331–2.
38. Armbruster C, Hassl A, Kriwanek S. Pneumocystis carinii coloniza-
tion in the absence of immunosuppression. Scand J Infect Dis
1997;29:591–3.
39. Sing A, Roggenkamp A, Autenrieth IB, Heesemann J. Pneumocystis
carinii carriage in immunocompetent patients with primary pul-
monary disorders as detected by single or nested PCR. J Clin
Microbiol 1999;37:3409–10.
40. Miller RF, Ambrose HE, Wakefield AE. Pneumocystis carinii f. sp.
hominis DNA in immunocompetent health care workers in contact
with patients with P. carinii pneumonia. J Clin Microbiol
2001;39:3877–82.
Address for correspondence: Gilles Nevez, Department of Parasitology,
Mycology and Travel Medicine, University Hospital Centre, 1 avenue
René Laennec, 80054 Amiens, France, EU; fax: 33-3-22-45-56-53; email:
nevez.gilles@chu-amiens.fr
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 4, April 2004 673
Pneumocystis jirovecii DHPS Genotypes, France
Search   past   issues   of   EID   at   www.cdc.gov/eid